ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $597,025 | -12.2% | 36,740 | -0.0% | 0.76% | +73.5% |
| Q1 2024 | $679,600 | -39.9% | 36,755 | +1.8% | 0.44% | -35.5% |
| Q4 2023 | $1,130,604 | +231.8% | 36,110 | +120.8% | 0.68% | +213.9% |
| Q3 2023 | $340,797 | -13.1% | 16,353 | -0.1% | 0.22% | -21.2% |
| Q2 2023 | $392,014 | +27.2% | 16,368 | -0.1% | 0.27% | -14.4% |
| Q1 2023 | $308,272 | +115791.7% | 16,380 | -2.1% | 0.32% | +69.3% |
| Q4 2022 | $266 | -99.9% | 16,739 | -0.0% | 0.19% | -18.2% |
| Q3 2022 | $274,000 | +19.7% | 16,743 | +2.8% | 0.23% | +32.8% |
| Q2 2022 | $229,000 | -42.0% | 16,281 | -0.1% | 0.17% | -23.3% |
| Q1 2022 | $395,000 | +1.5% | 16,290 | -2.3% | 0.23% | +25.4% |
| Q4 2021 | $389,000 | +40.4% | 16,665 | -0.0% | 0.18% | +79.2% |
| Q3 2021 | $277,000 | -35.0% | 16,668 | -4.6% | 0.10% | -28.9% |
| Q2 2021 | $426,000 | -5.5% | 17,479 | +0.0% | 0.14% | -49.3% |
| Q1 2021 | $451,000 | -52.3% | 17,472 | -23.8% | 0.28% | -45.8% |
| Q3 2020 | $945,000 | -14.6% | 22,916 | +0.3% | 0.52% | -21.1% |
| Q2 2020 | $1,107,000 | +14.7% | 22,847 | 0.0% | 0.66% | +56.7% |
| Q1 2020 | $965,000 | +2.7% | 22,847 | +4.0% | 0.42% | +25.5% |
| Q4 2019 | $940,000 | +19.9% | 21,963 | +0.8% | 0.33% | -23.1% |
| Q3 2019 | $784,000 | +65.8% | 21,796 | +23.2% | 0.43% | +132.8% |
| Q2 2019 | $473,000 | +91.5% | 17,697 | +92.3% | 0.19% | +104.4% |
| Q1 2019 | $247,000 | -7.1% | 9,203 | -28.2% | 0.09% | -79.8% |
| Q3 2018 | $266,000 | -3.6% | 12,825 | +4.5% | 0.45% | +309.1% |
| Q1 2018 | $276,000 | -25.4% | 12,273 | 0.0% | 0.11% | -39.2% |
| Q4 2017 | $370,000 | -15.3% | 12,273 | +5.7% | 0.18% | -59.6% |
| Q3 2017 | $437,000 | -47.6% | 11,607 | -59.9% | 0.45% | +4.7% |
| Q4 2016 | $834,000 | +124.2% | 28,913 | +147.2% | 0.43% | +1088.9% |
| Q3 2016 | $372,000 | – | 11,696 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
| GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
| Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
| Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
| Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
| SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
| Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
| Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
| PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |